TWiV notes Ashish Jha’s call for doctors to combat a vacuum of medical information while ignoring our contributions, China CDC’s surveillance of SARS-CoV-2 at the Huanan Seafood Market, and an experimental infectious attenuated COVID-19 vaccine that elicits superior mucosal and systemic immunity in hamsters.

In his weekly clinical update, Dr. Griffin discusses the White House COVID adviser calling on doctors to combat a vacuum of medical information, adeno-associated virus type 2 in US children with acute severe hepatitis, genomic investigations of unexplained acute hepatitis in children, surveillance of SARS-CoV-2 at the Huanan seafood market, vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Canada, effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5–17, prevalence and characteristics associated with post–COVID-19 condition among non-hospitalized adolescents and young adults, within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals, live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters, Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2, COVID-19 convalescent plasma utilization in the United States, FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19, anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO), anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19, triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients, and the breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of long COVID symptoms.

In his weekly clinical update, Dr. Griffin discusses how antibiotics don’t reduce risk of death from viral respiratory infections, norovirus infections continue to rise in the US, ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample, maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization, association of treatment with Nirmatrelvir and the risk of Post–COVID-19 condition, mechanically ventilated patients with COVID-19 had a higher chance of in-hospital death if treated with high-flow nasal cannula oxygen before intubation, high-flow nasal cannula and outcomes in COVID-19, severe infection and risk of Cardiovascular disease, and the risk factors associated with post−COVID-19 condition.

TWiV discusses genetic evidence of susceptible wildlife in SARS-CoV-2 positive samples at the Huanan Wholesale Seafood Market, polio cases in African linked to a new polio vaccine that was designed to not cause the disease, and structural conservation of hepatitis B virus capsid proteins over millions of years despite a shift from a naked to an enveloped capsid.

In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.

TWiV reveals how treatment with remdesivir for COVID-19 resolved a chronic poliovirus infection in an immunocompromised patient, and the finding that infection with SARS-CoV-2 leads to an increase in new and preexisting autoantibodies.

In his weekly clinical update, Dr. Griffin discusses clearance of longstanding, immune-deficiency-associated, vaccine-derived poliovirus infection following remdesivir therapy for chronic SARS-CoV-2 infection, SARS-CoV-2 exposure in New York City rats, clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea, exhaled breath aerosol shedding of SARS-CoV-2 variants, outpatient treatment of COVID-19 and the development of long COVID over 10 months, Nirmatrelvir and the risk of post-acute sequelae of COVID-19, assessment of the risk of venous thromboembolism in nonhospitalized patients with COVID-19, and the optimal duration of systemic corticosteroids in COVID-19 treatment.

On this episode of TWiV, the observation that the 1918 influenza virus is not lethal in nonhuman primates and implications for studies on viral virulence, and mRNA vaccines that control and resolve human papillomavirus-associated cancers in mice.